Andreas Lundqvist

Andreas Lundqvist publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Andreas Lundqvist sits on this spectrum.

Andreas Lundqvist D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Andreas Lundqvist sits on this spectrum.

Best Publications

• Cancer classification using the Immunoscore: a worldwide task force

  Jérôme Galon;Franck Pagès;Francesco M Marincola;Francesco M Marincola;Helen K Angell;Helen K Angell

  961
  Citations

• Heat-shock proteins as activators of the innate immune system

  Robert P.A Wallin;Andreas Lundqvist;Solveig H Moré;Arne von Bonin

  766
  Citations

• Inhibition of Tumor-Derived Prostaglandin-E2 Blocks the Induction of Myeloid-Derived Suppressor Cells and Recovers Natural Killer Cell Activity

  Yumeng Mao;Dhifaf Sarhan;André Steven;Barbara Seliger

  302
  Citations

• Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells

  Maria Berg;Andreas Lundqvist;Philip McCoy;Leigh Samsel

  289
  Citations

• Regression of human kidney cancer following allogeneic stem cell transplantation is associated with recognition of an HERV-E antigen by T cells.

  Yoshiyuki Takahashi;Nanae Harashima;Sachiko Kajigaya;Hisayuki Yokoyama

  225
  Citations

• A phase I trial of DNA vaccination with a plasmid expressing prostate-specific antigen in patients with hormone-refractory prostate cancer

  M. Pavlenko;A.-K. Roos;A. Lundqvist;A. Palmborg

  223
  Citations

• CXCL10-induced migration of adoptively transferred human natural killer cells toward solid tumors causes regression of tumor growth in vivo

  Erik Wennerberg;Veronika Kremer;Richard Childs;Andreas Lundqvist

  210
  Citations

• The Role of CXC Chemokine Receptors 1–4 on Immune Cells in the Tumor Microenvironment

  Unknown

  207
  Citations

• NK cells and solid tumors: therapeutic potential and persisting obstacles

  Unknown

  204
  Citations

• Melanoma-Educated CD14+ Cells Acquire a Myeloid-Derived Suppressor Cell Phenotype through COX-2–Dependent Mechanisms

  Yumeng Mao;Isabel Poschke;Erik Wennerberg;Yago Pico de Coaña

  198
  Citations

• CD73 immune checkpoint defines regulatory NK cells within the tumor microenvironment

  Shi Yong Neo;Ying Yang;Ying Yang;Julien Record;Ran Ma

  196
  Citations

• IL-15 activates mTOR and primes stress-activated gene expression leading to prolonged antitumor capacity of NK cells.

  Yumeng Mao;Vincent van Hoef;Xiaonan Zhang;Xiaonan Zhang;Erik Wennerberg

  174
  Citations

• Bortezomib and Depsipeptide Sensitize Tumors to Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand: A Novel Method to Potentiate Natural Killer Cell Tumor Cytotoxicity

  Andreas Lundqvist;Scott I. Abrams;David S. Schrump;Gauri Alvarez

  173
  Citations

• Regression of human kidney cancer following allogeneic stem cell transplantation is associated with recognition of an HERV-E antigen by T cells

  Unknown

  171
  Citations

• Immunomodulatory Effects of IL-2 and IL-15; Implications for Cancer Immunotherapy

  Unknown

  167
  Citations

• Genetic engineering of human NK cells to express CXCR2 improves migration to renal cell carcinoma

  Unknown

  161
  Citations

• Tissue distribution and differential expression of melanocortin 1 receptor, a malignant melanoma marker.

  Salazar-Onfray F;López M;Lundqvist A;Aguirre A

  156
  Citations

• Ipilimumab treatment decreases monocytic MDSCs and increases CD8 effector memory T cells in long-term survivors with advanced melanoma.

  Yago Pico de Coana;Maria Wolodarski;Maria Wolodarski;Isabel Poschke;Yuya Yoshimoto

  153
  Citations

• Persistence of recipient plasma cells and anti-donor isohaemagglutinins in patients with delayed donor erythropoiesis after major ABO incompatible non-myeloablative haematopoietic cell transplantation.

  L. M. Griffith;J. P. McCoy;C. D. Bolan;D. F. Stroncek

  146
  Citations

• Overcoming graft rejection in heavily transfused and allo-immunised patients with bone marrow failure syndromes using fludarabine-based haematopoietic cell transplantation

  Ramaprasad Srinivasan;Yoshiyuki Takahashi;J. Philip McCoy;Igor Espinoza-Delgado

  139
  Citations